Xspray Pharma
ISIN: SE0009973563 | Ticker: XSPRAY | LEI: 549300NGRQCNZ3X4L157
Country: Sweden
Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development, the first XS004 dasatinib recently filed with the FDA. Xspray’s strategy is to improve the quality of life for cancer patients by launching improved PKI products with relevant medical benefits and cost effectiveness.
Xspray Pharma uses its innovative, patented RightSize™ technology to develop 505(b)(2) improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs), for the treatment of cancer. The segment is the second largest in oncology and where drug prices are very high.
Xspray Pharma applies a unique platform technology:
- Improves the solubility of the active ingredient
- Best-in-class for high dose strength for poorly soluble drugs
- Fully amorphous (non-infringing to many crystalline products patents)
2003
Served areaWorldwide
HeadquartersRåsundavägen 12, 16967 Solna – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 605,303,000.00 | 622,903,000.00 | 585,430,000.00 |
| Noncurrent Assets | N/A | 274,288,000.00 | 340,838,000.00 | 453,200,000.00 |
| Property Plant And Equipment | N/A | 42,669,000.00 | 44,601,000.00 | 64,603,000.00 |
| Intangible Assets Under Development | N/A | 231,618,000.00 | 296,236,000.00 | 385,597,000.00 |
| Other Noncurrent Receivables | N/A | N/A | 0.00 | 2,999,000.00 |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | N/A | 1,000.00 | 1,000.00 | 1,000.00 |
| Current Assets | N/A | 331,015,000.00 | 282,065,000.00 | 132,229,000.00 |
| Inventories | N/A | 0.00 | 6,199,000.00 | 8,552,000.00 |
| Trade And Other Current Receivables | N/A | 2,667,000.00 | 2,473,000.00 | 2,362,000.00 |
| Cash and cash equivalents | 209,872,000.00 | 325,598,000.00 | 271,881,000.00 | 120,166,000.00 |
| Equity And Liabilities | N/A | 605,303,000.00 | 622,903,000.00 | 585,430,000.00 |
| Equity | 373,715,000.00 | 582,587,000.00 | 591,752,000.00 | 556,019,000.00 |
| Issued Capital | N/A | 18,893,000.00 | 20,680,000.00 | 22,680,000.00 |
| Retained Earnings | N/A | -146,689,000.00 | -243,387,000.00 | -375,057,000.00 |
| Other Reserves | N/A | 976,000.00 | 976,000.00 | 976,000.00 |
| Additional Paidin Capital | N/A | 709,407,000.00 | 813,483,000.00 | 907,420,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 582,587,000.00 | 591,752,000.00 | 556,019,000.00 |
| Noncurrent Liabilities | N/A | 2,898,000.00 | 1,185,000.00 | 560,000.00 |
| Current Liabilities | N/A | 19,818,000.00 | 29,966,000.00 | 28,851,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 8,438,000.00 | 16,865,000.00 | 14,786,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 10,401,000.00 | 11,456,000.00 |
| Other Current Payables | N/A | 768,000.00 | 653,000.00 | 1,043,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Other Income | 1,364,000.00 | 656,000.00 | 2,180,000.00 |
| Profit Loss From Operating Activities | -53,457,000.00 | -97,953,000.00 | -133,073,000.00 |
| Finance Income | 1,053,000.00 | 1,259,000.00 | 1,415,000.00 |
| Finance Costs | 6,000.00 | 4,000.00 | 12,000.00 |
| Profit Loss Before Tax | -52,410,000.00 | -96,698,000.00 | -131,670,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | -52,410,000.00 | -96,698,000.00 | -131,670,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -52,410,000.00 | -96,698,000.00 | -131,670,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 7,689,000.00 | 8,870,000.00 | 9,533,000.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | N/A | -113,000.00 | 98,000.00 | 0.00 |
| Interest Paid Classified As Operating Activities | N/A | 8,000.00 | 4,000.00 | 147,000.00 |
| Interest Received Classified As Operating Activities | N/A | 674,000.00 | 1,878,000.00 | 1,611,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -47,792,000.00 | -51,607,000.00 | -110,179,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 383,000.00 | 0.00 | N/A |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 4,572,000.00 | 1,313,000.00 | 24,466,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -96,828,000.00 | -105,818,000.00 | -135,345,000.00 |
| Proceeds From Issuing Shares | N/A | 249,320,000.00 | 99,877,000.00 | 100,000,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 936,000.00 | 2,154,000.00 | 2,128,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 260,345,000.00 | 103,708,000.00 | 93,809,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 115,726,000.00 | -53,717,000.00 | -151,715,000.00 |
| Cash and cash equivalents | 209,872,000.00 | 325,598,000.00 | 271,881,000.00 | 120,166,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 30.11.23 | Anders Bladh | Other | Other | SEK 12,000,000.00 |
| 30.11.23 | Anders Bladh | Other | Other | EUR 965,800.00 |
| 30.11.23 | Anders Bladh | Other | Other | SEK 65,120.00 |
| 30.11.23 | Torbjörn Koivisto | Other | Other | SEK 40,000.00 |
| 27.11.23 | Anders Bladh | Other | Buy | SEK 198,650.00 |
| 21.11.23 | Anders Bladh | Other | Buy | SEK 395,000.00 |
| 20.11.23 | Anders Bladh | Other | Buy | SEK 394,900.00 |
| 15.11.23 | Anders Bladh | Other | Buy | SEK 390,200.00 |
| 13.11.23 | Anders Bladh | Other | Buy | SEK 281,855.27 |
| 10.11.23 | Anders Bladh | Other | Buy | SEK 1,578,925.56 |
SE0009973563
LEI549300NGRQCNZ3X4L157
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.